Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Capital Expenditures (2020 - 2025)

Silence Therapeutics' Capital Expenditures history spans 6 years, with the latest figure at $3000.0 for Q3 2025.

  • On a quarterly basis, Capital Expenditures rose 104.71% to $3000.0 in Q3 2025 year-over-year; TTM through Dec 2025 was $55000.0, a 34.0% decrease, with the full-year FY2025 number at $55000.0, down 73.93% from a year prior.
  • Capital Expenditures hit $3000.0 in Q3 2025 for Silence Therapeutics, down from $48000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for SLN hit a ceiling of $2.8 million in Q4 2021 and a floor of -$613602.7 in Q2 2021.
  • Historically, Capital Expenditures has averaged $115614.4 across 5 years, with a median of -$8152.4 in 2021.
  • Biggest five-year swings in Capital Expenditures: tumbled 1437.36% in 2021 and later skyrocketed 2164.2% in 2024.
  • Tracing SLN's Capital Expenditures over 5 years: stood at $2.8 million in 2021, then plummeted by 88.5% to $324901.1 in 2022, then crashed by 66.0% to $110462.5 in 2023, then crashed by 43.87% to $62000.0 in 2024, then plummeted by 95.16% to $3000.0 in 2025.
  • Business Quant data shows Capital Expenditures for SLN at $3000.0 in Q3 2025, $48000.0 in Q2 2025, and $4000.0 in Q1 2025.